Fulcrum Therapeutics’ (FULC) “Neutral” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Fulcrum Therapeutics (NASDAQ:FULC) in a report released on Thursday morning,Benzinga reports. They currently have a $4.00 price target on the stock.

FULC has been the topic of several other reports. Bank of America downgraded shares of Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and dropped their target price for the stock from $10.00 to $2.00 in a research report on Thursday, September 12th. Stifel Nicolaus downgraded shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and dropped their target price for the stock from $22.00 to $3.00 in a research report on Thursday, September 12th. Leerink Partners reissued a “market perform” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Thursday, September 12th. Leerink Partnrs downgraded shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 12th. Finally, Royal Bank of Canada cut shares of Fulcrum Therapeutics from an “outperform” rating to a “sector perform” rating and decreased their price target for the stock from $15.00 to $4.00 in a report on Thursday, September 12th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, Fulcrum Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $9.33.

Fulcrum Therapeutics Stock Down 9.3 %

Shares of Fulcrum Therapeutics stock traded down $0.31 during trading on Thursday, hitting $3.01. The stock had a trading volume of 1,176,073 shares, compared to its average volume of 989,785. The stock has a 50 day simple moving average of $3.86 and a 200 day simple moving average of $6.51. The company has a market capitalization of $187.82 million, a PE ratio of -9.84 and a beta of 2.24. Fulcrum Therapeutics has a 1 year low of $2.87 and a 1 year high of $13.70.

Institutional Trading of Fulcrum Therapeutics

Institutional investors have recently made changes to their positions in the stock. National Bank of Canada FI lifted its stake in Fulcrum Therapeutics by 869.6% in the second quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock valued at $28,000 after acquiring an additional 4,000 shares during the last quarter. Profund Advisors LLC acquired a new stake in Fulcrum Therapeutics in the second quarter valued at approximately $68,000. China Universal Asset Management Co. Ltd. lifted its stake in Fulcrum Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock valued at $43,000 after acquiring an additional 4,701 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Fulcrum Therapeutics in the first quarter valued at approximately $115,000. Finally, Renaissance Technologies LLC acquired a new stake in Fulcrum Therapeutics in the second quarter valued at approximately $82,000. 89.83% of the stock is currently owned by institutional investors and hedge funds.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.